For patients, caregivers, and families living with retinal degenerative disease.
SunRegen is researching a potential treatment for people living with retinal degenerative diseases. These are serious, progressive conditions that can lead to significant vision loss or blindness; for most patients, no disease-modifying treatment exists today.
This section provides plain-language information about each disease. We believe patients and families deserve clear, honest information: about their condition, the current treatment landscape, and the state of research.
SunRegen is developing SBC003 for three primary retinal indications, with a fourth CNS neurodegeneration program in early research.
RP
A group of inherited diseases that progressively damage photoreceptor cells in the retina, causing night blindness, tunnel vision, and eventual blindness. Affects more than 100 known gene mutations.
99% of RP patients have no approved disease-modifying treatment.
Learn more →Dry AMD
The most common form of AMD, causing central vision loss through gradual degeneration of the macula. Geographic atrophy (advanced dry AMD) affects approximately 8–12 million people worldwide.
No approved oral treatment exists. Both approved injectables were rejected by the EMA.
Learn more →OA
Damage to the optic nerve causing loss of retinal ganglion cells and progressive vision loss. Includes primary, secondary, and glaucomatous optic atrophy. No neuroprotective treatments are currently approved.
No approved neuroprotective treatment exists for any form of optic atrophy.
Learn more →RP, Dry AMD, and Optic Atrophy look different on the surface; all three share a single final common pathway: the irreversible death of neurons through apoptosis. A neuroprotective therapy addresses this shared root cause regardless of what triggered it.
RP
Disease Trigger
Gene mutation (100+ subtypes)
Neurons Lost
Photoreceptors (rods first, then cones)
Dry AMD
Disease Trigger
Lipofuscin accumulation / complement dysregulation
Neurons Lost
RPE cells + photoreceptors (macula)
OA
Disease Trigger
Optic nerve injury / glaucoma / mitochondrial dysfunction
Neurons Lost
Retinal ganglion cells + axons
Final Common Pathway
Neuronal Apoptosis, in all three diseases
Once neurons die through apoptosis, they cannot regenerate. Current treatments try to slow each disease's specific trigger; none directly prevent the neurons from dying. SBC003 targets apoptosis itself, making it potentially effective across all three conditions.
In March 2025, the FDA approved Encelto (NT-501), the first neuroprotective retinal implant, for MacTel2, proving neuroprotection works in retinal disease.
SunRegen recommends connecting with established patient advocacy organizations for support, community, and the latest information on clinical trials.
Pioneering first-in-class orally bioavailable lipid therapeutics to halt neurodegeneration and restore vision. Clinical-stage. Basel, Switzerland.
© 2026 SunRegen Healthcare AG. All rights reserved.
Business Parc Reinach, Christoph Merian-Ring 11, 4153 Reinach, Switzerland
UID: CHE-295.245.274
This website contains forward-looking statements regarding future products, development plans, and business strategies. Actual results may differ materially. Nothing on this site constitutes medical or investment advice.